Orexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. The company is commercializing its proprietary product, Zubsolv® sublingual tablets, for treatment of opioid dependence, in the US. The Zubsolv sublingual tablet is an advanced formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of additional two approved and revenue generating products currently marketed under license in the US, EU and Japan.


April 21, 2017

Listen to the Q1 Report
2017 AudioCast


April 20 2017

Interim Report
Q1 2017